JPWO2022099159A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022099159A5
JPWO2022099159A5 JP2023527250A JP2023527250A JPWO2022099159A5 JP WO2022099159 A5 JPWO2022099159 A5 JP WO2022099159A5 JP 2023527250 A JP2023527250 A JP 2023527250A JP 2023527250 A JP2023527250 A JP 2023527250A JP WO2022099159 A5 JPWO2022099159 A5 JP WO2022099159A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
nucleic acid
target nucleic
composition
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548584A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058495 external-priority patent/WO2022099159A1/en
Publication of JP2023548584A publication Critical patent/JP2023548584A/ja
Publication of JPWO2022099159A5 publication Critical patent/JPWO2022099159A5/ja
Pending legal-status Critical Current

Links

JP2023527250A 2020-11-08 2021-11-08 オリゴヌクレオチド組成物及びその方法 Pending JP2023548584A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063111079P 2020-11-08 2020-11-08
US63/111,079 2020-11-08
US202163175036P 2021-04-14 2021-04-14
US63/175,036 2021-04-14
US202163188415P 2021-05-13 2021-05-13
US63/188,415 2021-05-13
US202163196178P 2021-06-02 2021-06-02
US63/196,178 2021-06-02
US202163248520P 2021-09-26 2021-09-26
US63/248,520 2021-09-26
PCT/US2021/058495 WO2022099159A1 (en) 2020-11-08 2021-11-08 Oligonucleotide compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2023548584A JP2023548584A (ja) 2023-11-17
JPWO2022099159A5 true JPWO2022099159A5 (enExample) 2024-11-20

Family

ID=81456778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527250A Pending JP2023548584A (ja) 2020-11-08 2021-11-08 オリゴヌクレオチド組成物及びその方法

Country Status (8)

Country Link
EP (1) EP4240849A1 (enExample)
JP (1) JP2023548584A (enExample)
KR (1) KR20230118716A (enExample)
AU (1) AU2021373062A1 (enExample)
CA (1) CA3197311A1 (enExample)
IL (1) IL302558A (enExample)
MX (1) MX2023005326A (enExample)
WO (1) WO2022099159A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
CN108025089A (zh) 2015-07-22 2018-05-11 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2017210647A1 (en) 2016-06-03 2017-12-07 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
CN109477103A (zh) 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ 单链rna-编辑寡核苷酸
EP3507366B1 (en) 2016-09-01 2020-10-07 ProQR Therapeutics II B.V. Chemically modified single-stranded rna-editing oligonucleotides
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
US11597927B2 (en) 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CA3072076A1 (en) 2017-08-08 2019-02-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
SG11202000276YA (en) 2017-09-18 2020-04-29 Wave Life Sciences Ltd Technologies for oligonucleotide preparation
BR112020020670A2 (pt) 2018-04-12 2021-03-02 Wave Life Sciences Ltd. composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo
TWI844541B (zh) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 寡核苷酸組成物及其使用方法
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2022046667A1 (en) * 2020-08-24 2022-03-03 Wave Life Sciences Ltd. Cells and non-human animals engineered to express adar1 and uses thereof
US20250034564A1 (en) * 2021-06-29 2025-01-30 Korro Bio, Inc. Methods and Compositions for ADAR-Mediated Editing
KR20240063964A (ko) * 2021-09-26 2024-05-10 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 방법
WO2023049477A2 (en) * 2021-09-26 2023-03-30 Wave Life Sciences Ltd. Compositions for editing mecp2 transcripts and methods thereof
WO2023069603A1 (en) * 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
US20260027237A1 (en) 2022-07-15 2026-01-29 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
JP2025525564A (ja) * 2022-07-18 2025-08-05 エフ. ホフマン-ラ ロシュ アーゲー オリゴヌクレオチドの編集
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
JP2025536808A (ja) 2022-11-24 2025-11-07 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップ 遺伝性hfeヘモクロマトーシスの治療のためのアンチセンスオリゴヌクレオチド
WO2024114908A1 (en) 2022-11-30 2024-06-06 Eberhard Karls Universität Tübingen Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
JP2025540146A (ja) 2022-12-09 2025-12-11 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 心血管疾患の治療のためのアンチセンスオリゴヌクレオチド
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
EP4669753A1 (en) 2023-02-20 2025-12-31 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
EP4669749A1 (en) 2023-02-21 2025-12-31 Vib Vzw OLIGONUCLEOTIDES TO MODULATE SYNAPTOGYRIN-3 EXPRESSION
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
CN121002181A (zh) 2023-03-27 2025-11-21 ProQR治疗上市公司Ⅱ 用于治疗肝脏疾病的反义寡核苷酸
WO2024220934A1 (en) 2023-04-21 2024-10-24 University Of Rochester Nucleic acid molecules for pseudouridylation
CN116444593B (zh) * 2023-04-28 2023-12-26 南通大学 一种7-脱氮鸟苷亚磷酰胺单体的合成方法
TW202516003A (zh) 2023-06-16 2025-04-16 荷蘭商Proqr治療上市公司Ii 用於治療神經退化性疾病之反義寡核苷酸
WO2025015338A1 (en) * 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025036984A1 (en) 2023-08-15 2025-02-20 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025072881A2 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025072862A1 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025073902A1 (en) 2023-10-06 2025-04-10 Eberhard Karls Universität Tübingen Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing
WO2025083268A1 (en) 2023-10-20 2025-04-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) * 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025160090A1 (en) * 2024-01-22 2025-07-31 Wave Life Sciences Ltd. Technol. ogies useful for oligonucleotide preparation
WO2025172372A1 (en) 2024-02-12 2025-08-21 Airna Corporation Conjugate for targeted delivery of an antisense oligonucleotide
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
GB202405143D0 (en) 2024-04-11 2024-05-29 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of poly-q disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9975916B2 (en) * 2012-11-06 2018-05-22 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
EP3507366B1 (en) * 2016-09-01 2020-10-07 ProQR Therapeutics II B.V. Chemically modified single-stranded rna-editing oligonucleotides
JP7364472B2 (ja) * 2017-05-18 2023-10-18 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化された核酸編集のための系、方法、及び組成物
WO2018237194A1 (en) * 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
BR112022006205A2 (pt) * 2019-10-06 2022-07-19 Wave Life Sciences Ltd Oligonucleotídeo; composição farmacêutica; composição de oligonucleotídeo; fosforamidita; método de preparação de um oligonucleotídeo ou composição; método para caracterizar um oligonucleotídeo ou uma composição; método para modificar uma adenosina alvo em um ácido nucleico alvo; método para desaminar uma adenosina alvo em um ácido nucleico alvo; método para prevenção ou tratamento de uma afecção, distúrbio ou doença passível de uma mutação de g para a; e composto, oligonucleotídeo, composição ou método

Similar Documents

Publication Publication Date Title
JPWO2022099159A5 (enExample)
JP2025165976A5 (enExample)
JPWO2021071858A5 (enExample)
TW202307207A (zh) 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法
JPWO2020227691A5 (enExample)
JPWO2021071788A5 (enExample)
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP2018528781A5 (enExample)
JPH09511250A (ja) 核酸治療に有用な修飾オリゴヌクレオチド及び中間体
JPWO2019217784A5 (enExample)
JPWO2020118246A5 (enExample)
WO2001085751A1 (en) Polymeric compounds useful as prodrugs
JP2019534009A5 (enExample)
JP7724259B2 (ja) 新規のチオホスホラミダイト
JP2021515784A (ja) 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法
KR20200104347A (ko) 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
US20160122372A1 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
JP2000512630A (ja) 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体
JPWO2023049477A5 (enExample)
JPWO2019217708A5 (enExample)
JPWO2023049475A5 (enExample)
JP2018518167A5 (enExample)
WO2021157730A1 (ja) 核酸医薬とその使用
JPWO2019140452A5 (enExample)
JPH1135595A (ja) アンチセンスオリゴヌクレオチド及びそれを用いた制癌剤